Belinostat

FDA Drug Profile — Beleodaq

Belinostat is listed in the FDA National Drug Code directory with 4 NDC codes, marketed under brand name including Beleodaq. Available dosage forms: injection, powder, lyophilized, for solution, powder.

Drug details

Generic Name
Belinostat
Brand Names
Beleodaq
Application Number
NDA206256
Sponsor
Acrotech Biopharma Inc
NDC Codes
4
Dosage Forms
INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION, POWDER
Routes
INTRAVENOUS
Active Ingredients
BELINOSTAT

Indications and Usage

1 INDICATIONS AND USAGE Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response [ see Clinical Studies ( 14 )]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. Beleodaq is a histone deacetylase inhibitor indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.( 1 )

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.